Pfm 30 Under 40 for 2017
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
HEALTHCARE SECTOR BULLETIN QUADRIA CAPITAL March 2015: Issue 20
HEALTHCARE SECTOR BULLETIN QUADRIA CAPITAL March 2015: Issue 20 HEALTHCARE TRENDS & IMPACT STORIES Country: Vietnam Headline: More private investments called for improving Vietnam’s healthcare sector Summary: While public hospitals are hugely over-crowded the patient-bed occupancy rate in the private sector remains rather low at many private hospitals. A recent Ministry of Health (MoH) report showed that only 5 per cent of private hospitals reported a full patient bed occupancy rate while the rate is as low from 20 to 60 per cent at 56 per cent of these private units. Head of MoH’s Financial Planning Department Nguyen Nam Lien said he believes the bottleneck would be addressed through gradually reducing subsidies the public receive at their normal hospitals. “This will stimulate the public into using the private sector facilities,” Lien said. “Support will go directly to medical insurance beneficiaries instead of going to hospitals as previously,” Lien said. This mechanism will encourage people to buy medical insurance, creating the conditions for the growth of the private sector. Promoting public-private partnership in medical services development is also important to attract private investors into the sector. The southern province of Dong Nai is a successful public-private model. Dong Nai general hospital’s second phase investment, carrying a price tag of VND1.2 trillion ($56 million) and having 700 patient-beds in scope, will go underway using private capital. Some private hospitals have seen growth such as the Hanoi French Hospital, Vimec international Hospital (Hanoi), Hoan My general hospital (Ho Chi Minh City), Hop Luc general hospital (Thanh Hoa) and Hoang Viet Thang general hospital (Hue). -
AGM Notice.Pmd
NOTICE Notice is hereby given that the 29th Annual General Meeting of Religare Enterprises Limited (“the Company”) will be held on Friday, September 13, 2013 at 4.30 P.M. at Air Force Auditorium, Subroto Park, New Delhi - 110010, to transact the following businesses: ORDINARY BUSINESS 1. To consider and adopt the audited Balance Sheet as at March 31, 2013, the Statement of Profit and Loss for the year ended on that date and the reports of the Board of Directors and Auditors thereon. 2. To appoint a Director in place of Mr. Ravi Umesh Mehrotra, who retires from office by rotation and being eligible, offers himself for re-appointment. 3. To appoint a Director in place of Mr. Padam Bahl, who retires from office by rotation and being eligible, offers himself for re- appointment. 4. To appoint Statutory Auditors and to fix their remuneration and in this regard to consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution. “RESOLVED THAT M/s Price Waterhouse, Chartered Accountants (Firm Registration No. 301112E) be and are hereby appointed as Statutory Auditors of the Company, to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company on such remuneration as shall be fixed by the Board of Directors.” SPECIAL BUSINESS 5. To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution: “RESOLVED THAT in accordance with the provisions of Section 257 and all other applicable provisions, if any, of the Companies Act, 1956 or any statutory modification(s) or re-enactment thereof, Mr. -
September 2014 Healthcare Sector Bulletin-10
HEALTHCARE SECTOR BULLETIN QUADRIA CAPITAL Issue 10: September 2014 HEALTHCARE TRENDS & IMPACT STORIES Country: India Headline: Dr. Amit Varma: The Healthcare Financier Summary: A critical care physician by education, Dr Amit is the Managing Partner of Quadria Capital's $300 million healthcare focused Private Equity Fund that invests in the healthcare sector across South and Southeast Asia. His team has domain experts who come with a lot of operating P&L experience, acting as strategic investors and getting hands on with the company. It is a strong belief of his that a business needs to be a regional powerhouse before trying to become national, which is what most of his portfolio companies are trying to achieve. One of the factors that he considers before investing is the management team's focus on overall profitability along with expansion. Healthcare private equity in Asia still have a long way to go and interest in the healthcare space will continue due to the huge demand supply gap, restricted public spending, and a large epidemic of life style diseases. Moving forward, the private equity landscape is changing. Unlike the past where it is just possible to make above average returns by just being a financial investor, the PE investors now need to have operating experience and deep domain skills to drive value creation. Link The Healthcare Executive, Vol 3 Issue 7, http://issuu.com/healthcareexecutive/docs/he_august_2014 (Full article is enclosed at Page 33 of this newsletter) Country: India Headline: Ex-Goldman India Head Lauds Hands–On Approach for Private Equity Summary: India’s private equity industry is entering a new chapter, now that the excesses of the last private-equity rush to the country have died down. -
DTC Participant Alphabetical Listing June 2019.Xlsx
DTC PARTICPANT REPORT (Alphabetical Sort ) Month Ending - June 30, 2019 PARTICIPANT ACCOUNT NAME NUMBER ABN AMRO CLEARING CHICAGO LLC 0695 ABN AMRO SECURITIES (USA) LLC 0349 ABN AMRO SECURITIES (USA) LLC/A/C#2 7571 ABN AMRO SECURITIES (USA) LLC/REPO 7590 ABN AMRO SECURITIES (USA) LLC/ABN AMRO BANK NV REPO 7591 ALPINE SECURITIES CORPORATION 8072 AMALGAMATED BANK 2352 AMALGAMATED BANK OF CHICAGO 2567 AMHERST PIERPONT SECURITIES LLC 0413 AMERICAN ENTERPRISE INVESTMENT SERVICES INC. 0756 AMERICAN ENTERPRISE INVESTMENT SERVICES INC./CONDUIT 7260 APEX CLEARING CORPORATION 0158 APEX CLEARING CORPORATION/APEX CLEARING STOCK LOAN 8308 ARCHIPELAGO SECURITIES, L.L.C. 0436 ARCOLA SECURITIES, INC. 0166 ASCENSUS TRUST COMPANY 2563 ASSOCIATED BANK, N.A. 2257 ASSOCIATED BANK, N.A./ASSOCIATED TRUST COMPANY/IPA 1620 B. RILEY FBR, INC 9186 BANCA IMI SECURITIES CORP. 0136 BANK OF AMERICA, NATIONAL ASSOCIATION 2236 BANK OF AMERICA, NA/GWIM TRUST OPERATIONS 0955 BANK OF AMERICA/LASALLE BANK NA/IPA, DTC #1581 1581 BANK OF AMERICA NA/CLIENT ASSETS 2251 BANK OF CHINA, NEW YORK BRANCH 2555 BANK OF CHINA NEW YORK BRANCH/CLIENT CUSTODY 2656 BANK OF MONTREAL, CHICAGO BRANCH 2309 BANKERS' BANK 2557 BARCLAYS BANK PLC NEW YORK BRANCH 7263 BARCLAYS BANK PLC NEW YORK BRANCH/BARCLAYS BANK PLC-LNBR 8455 BARCLAYS CAPITAL INC. 5101 BARCLAYS CAPITAL INC./LE 0229 BB&T SECURITIES, LLC 0702 BBVA SECURITIES INC. 2786 BETHESDA SECURITIES, LLC 8860 # DTCC Confidential (Yellow) DTC PARTICPANT REPORT (Alphabetical Sort ) Month Ending - June 30, 2019 PARTICIPANT ACCOUNT NAME NUMBER BGC FINANCIAL, L.P. 0537 BGC FINANCIAL L.P./BGC BROKERS L.P. 5271 BLOOMBERG TRADEBOOK LLC 7001 BMO CAPITAL MARKETS CORP. -
HEALTHCARE SECTOR BULLETIN QUADRIA CAPITAL Issue 5: June 2014
HEALTHCARE SECTOR BULLETIN QUADRIA CAPITAL Issue 5: June 2014 HEALTHCARE TRENDS & IMPACT STORIES Country: Indonesia Headline: Maximize the fresh opportunities for healthcare distribution in the fast-growing Indonesian provinces to boost services for principals and consumers Summary: Government decentralization has increased the flow of funds to provinces that were previously being left behind, often in spite of the fact that some of those provinces were key sources of the nation’s wealth, such as coal, oil and gas, timber and palm oil. Now these provinces are finally starting to benefit from having a greater share of government funds and this is being reflected in comparative growth figures. The consequence for the healthcare sector is that growth will continue to be higher in the provinces as consumer purchasing power increases in those regions at a rate greater than in the major cities. In turn this will require greater attention to the provinces for achieving the desired availability of medicines and, in the case of consumer health products, more visibility. Link http://www.zuelligpharma.com.sg/sites/default/files/MP53%20Feature%20Story.pdf Country: Asia Headline: Hospital companies prepare to meet surging demand for health care in Asia Summary: Although Asia’s emerging economies are slowing, the rise of their middle classes is continuing. In Indonesia the number of middle- and upper-income consumers is expected to swell from 74m in 2013 to 141m by 2020, predicts the Boston Consulting Group. Rising incomes mean rising demand for health care. The average Chinese city-dweller’s health spending more than doubled between 2002 and 2010, estimates PwC, a firm of consultants. -
NB Private Equity Partners: Overview Presentation
NB Private Equity Partners: Overview Presentation Financial Information as of 30 September 2019, Unless Otherwise Noted November 2019 Why Invest in NBPE? Key Investment Merits Access to a portfolio of direct private equity investments, sourced from over 55 distinct private equity firms; diversified private company exposure without single GP risk Sourcing and execution through Neuberger Berman’s ~$80 billion private equity business Strong Historic Performance Capital appreciation from equity investments and income through dividend No second layer of management fees or carried interest on vast majority of direct investments, offering significant fee efficiency vs listed fund of funds vehicles1 1. Approximately 98% of the direct investment portfolio (measured on 30 September 2019 fair value) is on a no management fee, no carry basis to underlying third-party GPs. Key Information Document is available on NBPE’s website. NB PRIVATE EQUITY PARTNERS INVESTOR UPDATE 2 NBPE Position in the Listed Private Equity Landscape NBPE is focused on direct investments, invested alongside over 55 private equity sponsors Hyper Diversified Fund of Funds • Primary & Secondary, some co-investment NB Private Equity Partners exposure • Dual fee layer • Multi-Sponsor Exposure • Need to over-commit or • Single layer of fees on majority of 1 suffer cash drag direct investments Direct Focus, Single GP • Single GP Concentration Concentrated • Single fee layer at vehicle level, carry typically higher than NBPE Lower Higher Fee Efficiency Note: as of 30 September 2019. The above graphic is intended to be a representation of the funds’ investment strategy of direct vs fund investments and investments into third-party or funds managed by an affiliated investment manager of the listed company. -
Fintech Monthly Market Update | July 2021
Fintech Monthly Market Update JULY 2021 EDITION Leading Independent Advisory Firm Houlihan Lokey is the trusted advisor to more top decision-makers than any other independent global investment bank. Corporate Finance Financial Restructuring Financial and Valuation Advisory 2020 M&A Advisory Rankings 2020 Global Distressed Debt & Bankruptcy 2001 to 2020 Global M&A Fairness All U.S. Transactions Restructuring Rankings Advisory Rankings Advisor Deals Advisor Deals Advisor Deals 1,500+ 1 Houlihan Lokey 210 1 Houlihan Lokey 106 1 Houlihan Lokey 956 2 JP Morgan 876 Employees 2 Goldman Sachs & Co 172 2 PJT Partners Inc 63 3 JP Morgan 132 3 Lazard 50 3 Duff & Phelps 802 4 Evercore Partners 126 4 Rothschild & Co 46 4 Morgan Stanley 599 23 5 Morgan Stanley 123 5 Moelis & Co 39 5 BofA Securities Inc 542 Refinitiv (formerly known as Thomson Reuters). Announced Locations Source: Refinitiv (formerly known as Thomson Reuters) Source: Refinitiv (formerly known as Thomson Reuters) or completed transactions. No. 1 U.S. M&A Advisor No. 1 Global Restructuring Advisor No. 1 Global M&A Fairness Opinion Advisor Over the Past 20 Years ~25% Top 5 Global M&A Advisor 1,400+ Transactions Completed Valued Employee-Owned at More Than $3.0 Trillion Collectively 1,000+ Annual Valuation Engagements Leading Capital Markets Advisor >$6 Billion Market Cap North America Europe and Middle East Asia-Pacific Atlanta Miami Amsterdam Madrid Beijing Sydney >$1 Billion Boston Minneapolis Dubai Milan Hong Kong Tokyo Annual Revenue Chicago New York Frankfurt Paris Singapore Dallas -
MRAC Minutes for December 11, 2019
MINUTES OF THE MEETING OF THE U.S. COMMODITY FUTURES TRADING COMMISSION’S MARKET RISK ADVISORY COMMITTEE December 11, 2019 The Market Risk Advisory Committee (MRAC or Committee) convened for a public meeting on December 11, 2019, at 9:30 a.m., at the U.S. Commodity Futures Trading Commission’s (CFTC or Commission) Headquarters Conference Center, located at Three Lafayette Centre, 1155 21st Street, NW, Washington, DC. The MRAC received reports from its subcommittees on Climate-Related Market Risk (CRMR), Market Structure, Central Counterparty (CCP) Risk and Governance (CCPRG), and Interest Rate Benchmark Reform (IRBR). Additionally, there would be a follow-up discussion on Central Counterparty Adjustments to Discounting/Price Alignment Interest Environment. The MRAC also discussed other issues involving the transition from the LIBOR to alternative risk-free reference rates (RFRs); including the recent consultation of the International Swaps and Derivatives Association (ISDA) on the final parameters for the spread and term adjustments that will apply to RFRs if derivatives fallbacks are triggered. MRAC Members in Attendance Nadia Zakir, MRAC Chair and Executive Vice President and Deputy General Counsel, Pacific Investment Management Company LLC (PIMCO) B. Salman Banaei, Executive Director, Global Head of Clearance and Settlement, IHS Markit Stephen Berger, Managing Director and Global Head of Government & Regulatory Policy, Citadel Dr. Richard Berner, Clinical Professor of Management Practice in Finance and Co-Director of the Stern Volatility -
Overview Presentation Financial Information As of 31 August 2019, Unless Otherwise Noted October 2019 Why Invest in NBPE? Key Investment Merits
NB Private Equity Partners: Overview Presentation Financial Information as of 31 August 2019, Unless Otherwise Noted October 2019 Why Invest in NBPE? Key Investment Merits Access to a portfolio of direct private equity investments, sourced from over 55 distinct private equity firms; diversified private company exposure without single GP risk Sourcing and execution through Neuberger Berman’s $74 billion private equity business Strong Historic Performance: 13.0% YTD IRR on direct equity investments; total portfolio 11.5% YTD IRR. Three year direct equity investments gross IRR of 18.6%; three year total portfolio gross IRR of 15.1% Capital appreciation from equity investments and income through dividend No second layer of management fees or carried interest on vast majority of direct investments, offering significant fee efficiency vs listed fund of funds vehicles1 1. Approximately 98% of the direct investment portfolio (measured on 31 August 2019 fair value) is on a no management fee, no carry basis to underlying third-party GPs. Key Information Document is available on NBPE’s website. NB PRIVATE EQUITY PARTNERS INVESTOR UPDATE 2 NBPE Position in the Listed Private Equity Landscape NBPE is focused on direct investments, invested alongside over 55 private equity sponsors Hyper Diversified Fund of Funds • Primary & Secondary, some co-investment NB Private Equity Partners exposure • Dual fee layer • Multi-Sponsor Exposure • Need to over-commit or • Single layer of fees on majority of 1 suffer cash drag direct investments Direct Focus, Single GP • Single GP Concentration Concentrated • Single fee layer at vehicle level, carry typically higher than NBPE Lower Higher Fee Efficiency Note: as of 31 August 2019. -
Politecnico Di Torino
POLITECNICO DI TORINO Dipartimento di Ingegneria Gestionale e della Produzione Corso di Laurea Magistrale in Engineering and Management Framing of International Social-Impact Venture Capital Funds and of Their Management Teams, Behind and Beyond Performances Relatore Prof.ssa Elisa Ughetto Correlatori Prof. Giuseppe Scellato Prof.ssa Annalisa Croce Candidato Marina Berardi April 2019 1 Contents I LIST OF ACRONYMS AND ABBREVIATIONS .......................................................................................... 4 II LIST OF FIGURES .......................................................................................................................................... 5 CHAPTER 1 OVERVIEW................................................................................................................................... 7 1.1 ABSTRACT .............................................................................................................................................. 7 1.2 FRAMING LITERATURE ........................................................................................................................... 8 CHAPTER 2 SOCIAL INVESTMENT MARKET ......................................................................................... 13 2.1 SOCIAL FINANCIAL INSTRUMENTS ............................................................................................................... 13 2.2 ACTORS IN SOCIAL INVESTMENT MARKET ................................................................................................. -
Virtu Announces Fourth Quarter and Full Year 2020 Results
Virtu Announces Fourth Quarter and Full Year 2020 Results Authorizes Additional $70 Million Share Repurchase NEW YORK, NY, February 11, 2021 - Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the fourth quarter ended and full year ended December 31, 2020. Fourth Quarter 2020: • Net income of $197.7 million; Normalized Adjusted Net Income1 of $234.0 million • Basic earnings per share of $0.89 and diluted earnings per share of $0.88; Normalized Adjusted EPS1 of $1.18 • Total revenues of $676.7 million; Trading income, net, of $505.5 million; Adjusted Net Trading Income1 of $455.9 million • Adjusted EBITDA1 of $343.9 million; Adjusted EBITDA Margin1 of 75.4% • Additional $70 million share repurchase authorized, bringing total to $170 million authorized; $50 million executed to date Full Year 2020: • Net income of $1,120.9 million; Normalized Adjusted Net Income1 of $1,135.1 million • Basic earnings per share of $5.19 and diluted earnings per share of $5.16; Normalized Adjusted EPS1 of $5.76 • Total revenues of $3,239.3 million; Trading income, net, of $2,493.2 million; Adjusted Net Trading Income1 of $2,271.4 million • Adjusted EBITDA1 of $1,648.0 million; Adjusted EBITDA Margin1 of 72.6% The Virtu Financial, Inc. Board of Directors declared a quarterly cash dividend of $0.24 per share. This dividend is payable on March 15, 2021 to shareholders of record as of March 1, 2021. -
Usef-I Q2 2021
Units Cost Market Value U.S. EQUITY FUND-I U.S. Equities 88.35% Domestic Common Stocks 10X GENOMICS INC 5,585 868,056 1,093,655 1ST SOURCE CORP 249 9,322 11,569 2U INC 301 10,632 12,543 3D SYSTEMS CORP 128 1,079 5,116 3M CO 11,516 2,040,779 2,287,423 A O SMITH CORP 6,897 407,294 496,998 AARON'S CO INC/THE 472 8,022 15,099 ABBOTT LABORATORIES 24,799 2,007,619 2,874,948 ABBVIE INC 17,604 1,588,697 1,982,915 ABERCROMBIE & FITCH CO 1,021 19,690 47,405 ABIOMED INC 9,158 2,800,138 2,858,303 ABM INDUSTRIES INC 1,126 40,076 49,938 ACACIA RESEARCH CORP 1,223 7,498 8,267 ACADEMY SPORTS & OUTDOORS INC 1,036 35,982 42,725 ACADIA HEALTHCARE CO INC 2,181 67,154 136,858 ACADIA REALTY TRUST 1,390 24,572 30,524 ACCO BRANDS CORP 1,709 11,329 14,749 ACI WORLDWIDE INC 6,138 169,838 227,965 ACTIVISION BLIZZARD INC 13,175 839,968 1,257,422 ACUITY BRANDS INC 1,404 132,535 262,590 ACUSHNET HOLDINGS CORP 466 15,677 23,020 ADAPTHEALTH CORP 1,320 39,475 36,181 ADAPTIVE BIOTECHNOLOGIES CORP 18,687 644,897 763,551 ADDUS HOMECARE CORP 148 13,034 12,912 ADOBE INC 5,047 1,447,216 2,955,725 ADT INC 3,049 22,268 32,899 ADTALEM GLOBAL EDUCATION INC 846 31,161 30,151 ADTRAN INC 892 10,257 18,420 ADVANCE AUTO PARTS INC 216 34,544 44,310 ADVANCED DRAINAGE SYSTEMS INC 12,295 298,154 1,433,228 ADVANCED MICRO DEVICES INC 14,280 895,664 1,341,320 ADVANSIX INC 674 15,459 20,126 ADVANTAGE SOLUTIONS INC 1,279 14,497 13,800 ADVERUM BIOTECHNOLOGIES INC 1,840 7,030 6,440 AECOM 5,145 227,453 325,781 AEGLEA BIOTHERAPEUTICS INC 287 1,770 1,998 AEMETIS INC 498 6,023 5,563 AERSALE CORP